Fortem Financial Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Fortem Financial Group’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12	Closed	–	–	219
2020 Q4	$0	Buy	+12	New	+$449	﹤0.01%	463

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fortem Financial Group's CRBP Position: Q1 2021 in Review

Fortem Financial Group sold out of Corbus Pharmaceuticals (CRBP) in Q1 2021, closing a stake of 12 shares.

Fortem Financial Group first reported a position in CRBP in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2021.

Fortem Financial Group reported no remaining Corbus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Fortem Financial Group sold 12 Corbus Pharmaceuticals shares in Q1 2021.
Fortem Financial Group first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Fortem Financial Group's Corbus Pharmaceuticals position peaked at $0 in Q4 2020.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2021.

Based on Fortem Financial Group's 13F filing for Q1 2021, filed 20 Apr 2021.